Shanghai Cell Therapy Group (SHCell) recently entered into a six-year research collaborative project with Professor Qi-Long Ying from the University of Southern California (USC). Through the project, sponsored by $3.6 million from the Baize Plan Fund, the Ying laboratory aims to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.

To read more, visit https://stemcell.keck.usc.edu/shanghai-cell-therapy-group-launches-collaboration-with-usc-researcher-to-improve-the-ex-vivo-expansion-of-hematopoietic-stem-cells-for-clinical-applications.